Natco Pharma has reported results for first quarter ended June 30, 2017.
The company has reported a surge of 91.36% in its net profit at Rs 97.40 crore for the quarter under review as compared to Rs 50.90 crore for the same quarter in the previous year. Total income of the company increased by 31.60% at Rs 433.50 crore for Q1FY18 as compared Rs 329.40 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a surge of 97.26% in its net profit at Rs 93.70 crore for the quarter under review as compared to Rs 47.50 crore for the same quarter in the previous year. Total income of the company increased by 29.87% at Rs 448.70 crore for Q1FY18 as compared Rs 345.50 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: